Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

VJHemOnc is pleased to be a Media Partner for the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that was held in Paris, France, and online, on 23 - 26 April 2023. This meeting brought together physicians, nurses, clinical research technicians, and patients, to discuss the latest updates in the field of blood and marrow transplantation and cellular therapies.
View all videos

EBMT 2023

The 49th Annual Meeting of the EBMT
23–26 April 2023 | Paris, France / Online

EBMT 2023

The 49th Annual Meeting of the EBMT
23–26 April 2023 | Paris, France / Online
VJHemOnc is pleased to be a Media Partner for the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) that was held in Paris, France, and online, on 23 - 26 April 2023. This meeting brought together physicians, nurses, clinical research technicians, and patients, to discuss the latest updates in the field of blood and marrow transplantation and cellular therapies.
View all videos

Latest videos

View all videos
5:31
Cellular immunotherapy highlights from EBMT 2023
Mohamad Mohty • 25 Apr 2023
2:37
Weighing up the pros and cons of CAR-T therapy and bispecific antibodies in R/R DLBCL
Anna Sureda • 4 May 2023
3:10
GoCART ongoing projects: impact of prior therapy & alloSCT consolidation on CAR-T outcomes in ALL
Valentín Ortiz-Maldonado • 25 May 2023
3:57
Comparing BMT and CAR-T therapy: learnings for patient care and management
Natacha Bolaños • 25 Apr 2023

Transplantation

View all
3:25
Impact of microbiome signatures & production of intestinal metabolites on alloSCT outcomes
Erik Orberg • 28 Apr 2023
1:54
A novel clinical trial endpoint for acute GvHD
James Ferrara • 24 Apr 2023

Cellular Therapy

View all
5:32
CARBON: results of Phase I study of CTX110 allogeneic CRISPR-CAS9-engineered CAR-Ts in R/R LBCL
Joseph McGuirk • 24 Apr 2023
2:08
Advances in gene engineering technologies for NK cell-based immunotherapy
Evelyn Ullrich • 24 Apr 2023

Multiple Myeloma

View all
2:04
Using MRD negativity to measure depth of response & to discontinue treatment in multiple myeloma
Meral Beksac • 24 Apr 2023
1:31
The role of daratumumab in combination with lenalidomide as maintenance therapy in NDMM post-autoSCT
Elias Mai • 25 Apr 2023

Myeloproliferative Neoplasms

View all
1:56
Incorporating novel agents for myelofibrosis in the pre- and post-transplant settings
Katja Sockel • 25 Apr 2023
1:34
The role of allogeneic transplantation in myelofibrosis & patient eligibility for alloSCT
Jean-Jacques Kiladjian • 26 Apr 2023

Leukemia

View all
2:51
Outcomes of patients with B-ALL treated with inotuzumab and who have undergone alloSCT
David Marks • 24 Apr 2023
3:05
FORUM results: TBI vs myeloablative chemo-based conditioning pre-alloSCT in high-risk pediatric ALL
Christina Peters • 23 Apr 2023

Lymphoma

View all
1:15
The current status of CAR-T therapy in second-line DLBCL in Europe
Christian Chabannon • 23 Apr 2023
2:42
Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCT
Pau Abrisqueta • 28 Apr 2023

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals